Journal Mobile Options
Table of Contents
Vol. 23, No. 2, 2002
Issue release date: March–April 2002 (June 2002)
Section title: Review
Tumor Biol 2002;23:93–102
(DOI:10.1159/000059711)

Egr1 Transcription Factor: Multiple Roles in Prostate Tumor Cell Growth and Survival

Adamson E.D. · Mercola D.
aBurnham Institute, La Jolla, Calif., and bSidney Kimmel Cancer Center, San Diego, Calif., USA

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Review

Published online: 6/17/2002

Number of Print Pages: 10
Number of Figures: 1
Number of Tables: 1

ISSN: 1010-4283 (Print)
eISSN: 1423-0380 (Online)

For additional information: http://www.karger.com/TBI

Abstract

The transcription factor, Egr1, so-called because it is encoded by the immediate early growth response gene, Egr1, is rapidly induced by growth factors to transduce the proliferative signal. The induction of Egr1 by external stimuli is generally transient but appears to be sustained in some prostate tumor cell lines and tumors, suggesting that Egr1 stimulates tumor cell growth. In contradiction, in breast, lung and brain tumors, Egr1 expression is often absent or reduced and when re-expressed, results in growth suppression. Re-expression of Egr1 in tumor cells also leads to antiapoptotic activity, which would encourage tumor cell survival. Egr1 is also required for, or stimulates, the differentiation of several cell types. Another contradiction is that after stress stimuli to some cell types, Egr1 is required for programmed cell death or apoptosis in both normal and tumor cells. Egr1 also plays a role in tumor progression, through the hypoxic signal generated in growing tumors. Egr1 is highly induced under these conditions and its activities stimulate angiogenesis and improved survival of tumor cells. How this large agenda can be achieved lies in the choice of Egr1 target genes, and varying patterns of coordinated expression have been described, but the mechanisms for this choice are not clear. This review points to areas where research should be focussed.


  

Author Contacts

E.D. Adamson
La Jolla Cancer Research Center, The Burnham Institute
10901 North Torrey Pines Rd.
La Jolla, CA 92037 (USA)
Tel. +1 858 646 3137, Fax +1 858 646 3198, E-Mail eadamson@burnham.org

  

Article Information

Received: Received: September 21, 2001
Accepted after revision: December 10, 2001
Number of Print Pages : 10
Number of Figures : 1, Number of Tables : 1, Number of References : 141

  

Publication Details

Tumor Biology (Tumor Markers and Translational Cancer Research)
Founded 1980 as ‘Oncodevelopmental Biology and Medicine’ by the ISOBM, continued 1984–1986 as ‘Tumour Biology’
The Journal of the International Society for Oncodevelopmental Biology and Medicine (ISOBM)

Vol. 23, No. 2, Year 2002 (Cover Date: March-April 2002 (Released June 2002))

Journal Editor: T. Stigbrand, Umeå; Managing Editor: P.D. Rye, Oslo
ISSN: 1010–4283 (print), 1423–0380 (Online)

For additional information: http://www.karger.com/journals/tbi


Article / Publication Details

First-Page Preview
Abstract of Review

Published online: 6/17/2002

Number of Print Pages: 10
Number of Figures: 1
Number of Tables: 1

ISSN: 1010-4283 (Print)
eISSN: 1423-0380 (Online)

For additional information: http://www.karger.com/TBI


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.